RxDoctor Payments Data

Kerry Welch

American Fork, UTNPI 1346291796

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $700 and has fallen 73.6% since, to $185 in 2022.

$1,861in general payments, 2019–2025

Across 126 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$408
  • Amgen$282
  • Lilly USA, LLC$208
  • Takeda Pharmaceuticals U.S.A., Inc.$188
  • Sanofi-aventis U.S. LLC$143
  • Pfizer$70
  • plus $561 from 21 others

What the payments were for

  • Food & beverage$1,861100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Where these figures come from

Is this you, or does something look wrong? →